Oxford Cannabinoid Technologies Holdings Plc

Octavian Therapeutics Emerges with New Brand and £10M Fundraising Plan for Neuropathic Pain Drug Development

3 months ago

• OCT Holdings rebrands as Octavian Therapeutics, appointing Lord Mott as new Chair and establishing U.S. presence through Delaware-based subsidiary to accelerate growth in North America. • Company's lead candidate CB2 agonist successfully completed Phase 1 trials for diabetic peripheral neuropathy, with planned expansion into chemotherapy-induced neuropathy and IBS treatment. • Strategic £10M fundraising initiative launching March 2025 to advance clinical trials, facilitate IND filing, and expand AI-driven drug discovery platform.